Last reviewed · How we verify
Ebixa
At a glance
| Generic name | Ebixa |
|---|---|
| Sponsor | Konkuk University Medical Center |
| Target | Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Moderate to Severe Alzheimer's Type Dementia
Common side effects
Key clinical trials
- Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain (PHASE2)
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2, PHASE3)
- Pattern Separation in Major Depressive Disorder (PHASE1)
- Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) (EARLY_PHASE1)
- Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (PHASE3)
- Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial) (PHASE2)
- Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease (PHASE4)
- Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ebixa CI brief — competitive landscape report
- Ebixa updates RSS · CI watch RSS
- Konkuk University Medical Center portfolio CI